Geron Corp (GERN)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.00 (+0.05%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Geron Corp (GERN)
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Key Insights

Critical company metrics and information

  • Share Price

    $4.00

  • Market Cap

    $2.42 Billion

  • Total Outstanding Shares

    604.50 Million Shares

  • Total Employees

    141

  • Dividend

    No dividend

  • IPO Date

    July 31, 1996

  • SIC Description

    Pharmaceutical Preparations

  • Homepage

    https://www.geron.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow$30.95 Million
Net Cash Flow From Operating Activities$-215.61 Million
Net Cash Flow From Operating Activities, Continuing$-215.61 Million
Net Cash Flow From Investing Activities, Continuing$45.08 Million
Net Cash Flow From Financing Activities$201.49 Million
Net Cash Flow, Continuing$30.95 Million
Net Cash Flow From Investing Activities$45.08 Million
Net Cash Flow From Financing Activities, Continuing$201.49 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Net Income/Loss Available To Common Stockholders, Basic$-201.19 Million
Costs And Expenses$232.44 Million
Basic Earnings Per Share$0.32
Interest Expense, Operating$12.12 Million
Income/Loss From Continuing Operations After Tax$-201.19 Million
Operating Expenses$237.45 Million
Depreciation and Amortization$518000.00
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Preferred Stock Dividends And Other Adjustments$0.00
Income/Loss From Continuing Operations Before Tax$-201.19 Million
Other Operating Expenses$182.34 Million
Benefits Costs and Expenses$175.96 Million
Net Income/Loss Attributable To Parent$-201.19 Million
Revenues$29.48 Million
Diluted Earnings Per Share$0.32
Diluted Average Shares$1.30 Billion
Net Income/Loss$-201.19 Million
Basic Average Shares$1.30 Billion
Operating Income/Loss$-207.97 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Liabilities And Equity$444.95 Million
Fixed Assets$1.59 Million
Other Non-current Assets$45.30 Million
Current Assets$398.06 Million
Noncurrent Assets$46.89 Million
Equity$292.28 Million
Liabilities$152.67 Million
Wages$15.18 Million
Equity Attributable To Noncontrolling Interest$0.00
Assets$444.95 Million
Other Current Liabilities$109.02 Million
Noncurrent Liabilities$14.73 Million
Other Current Assets$377.77 Million
Equity Attributable To Parent$292.28 Million
Current Liabilities$137.93 Million
Inventory$20.28 Million
Accounts Payable$13.73 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
Earnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

ⓒ 2024 Financhle. All Rights Reserved.